| Methods |
Adequate allocation generation, double‐blind, no ITT |
| Participants |
Army recruits, USA |
| Interventions |
Coumermycin A1: 14 x 50 mg versus placebo |
| Outcomes |
Eradication, acquisition, failure serogroup
Follow‐up: 10 days |
| Notes |
Data extracted for 1) all (regardless of carrier status), 2) carriers only, 3) non‐carriers only |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Low risk |
Adequate allocation generation |
| Allocation concealment (selection bias) |
Unclear risk |
Unclear |
| Blinding of participants and personnel (performance bias)
All outcomes |
Low risk |
Double‐blind |
| Incomplete outcome data (attrition bias)
All outcomes |
Unclear risk |
No ITT |
| Selective reporting (reporting bias) |
Low risk |
No evidence |
| Other bias |
Low risk |
No evidence |
